Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome

Glintborg, Dorte; Støving, René Klinkby; Hagen, Claus; Hermann, Anne Pernille; Frystyk, Jan; Veldhuis, Johannes D.; Flyvbjerg, Allan; Andersen, Marianne

doi:10.1210/jc.2005-0615

Cited by 41 publications

(43 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with amenorrhea (period length Ͼ3 months) were examined randomly according to the protocol previously described (31,32). After initial examination, patients were randomized to pioglitazone (30 mg/d) or placebo treatment for 16 wk in a doubleblind fashion.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Glintborg

Andersen

Hagen

et al. 2008

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

125

107

View full text Add to dashboard Cite

Objective: Our objective was to investigate the effect of pioglitazone on bone mineral density (BMD) and bone turnover markers in polycystic ovary syndrome (PCOS). Design and Setting:We conducted a randomized, placebo-controlled study at an outpatient clinic at a university hospital.Patients: Thirty premenopausal patients with PCOS and 14 age-and weight-matched healthy females participated.Interventions: Pioglitazone (30 mg/d) or placebo was given for 16 wk. Main Outcome Measures: Measurements of BMD [hip (neck and total) and lumbar spine (L2-L4)], bone metabolic parameters [alkaline phosphatase (ALP), 25-hydroxyvitamin D, C-telopeptide of type I collagen (ICTP), osteocalcin, and PTH], endocrine profiles (testosterone, estradiol, and insulin), and body composition (waist to hip ratio, body mass index, and whole-body dual-energy x-ray absorptiometry scans) were performed. Results:Patients with PCOS had significantly higher levels of ICTP, fasting insulin, and testosterone than controls, whereas no differences were measured in ALP, PTH, body composition, or BMD.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The patient population in this study has been previously described (31,32). Thirty reproductive-aged Caucasian women with PCOS were included in the study.…”

Section: Subjectsmentioning

confidence: 99%

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Glintborg

Andersen

Hagen

et al. 2008

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

125

107

View full text Add to dashboard Cite

show abstract

“…RESEARCH DESIGN AND METHODS -The study subjects have previously been described in two articles on insulin sensitivity, IGF-1, and growth hormone levels during pioglitazone treatment in PCOS patients (12,13). In brief, 30 reproductive-age Caucasian women with PCOS were included.…”

Section: Diabetes Care 31:328-334 2008mentioning

confidence: 99%

“…Patients with amenorrhea (period length Ͼ3 months) were examined randomly. The evaluation program of included subjects was performed as previously described (12,13). Clinical examination.…”

Section: Examinationsmentioning

confidence: 99%

Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment

et al. 2008

Self Cite

View full text Add to dashboard Cite

OBJECTIVE -We investigated the relation between soluble CD36 (sCD36), risk markers of atherosclerosis and body composition, and glucose and lipid metabolism in polycystic ovary syndrome (PCOS).RESEARCH DESIGN AND METHODS -Thirty PCOS patients were randomized to 30 mg/day pioglitazone or placebo for 16 weeks. Fourteen weight-matched healthy female subjects were included as control subjects. sCD36, oxidized LDL (oxLDL), high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, euglycemic-hyperinsulinemic clamps, and whole-body dual-energy X-ray absorptiometry scans were performed. were significantly increased in PCOS patients versus control subjects (geometric mean Ϯ 2 SD). In PCOS, positive correlations were found between central fat mass and sCD36 (r ϭ 0.43), hsCRP (r ϭ 0.43), and IL-6 (r ϭ 0.42) (all P Ͻ 0.05). After adjusting for fat mass, sCD36 and oxLDL correlated inversely with measures of insulinstimulated glucose metabolism and positively with lipid oxidation during insulin stimulation in PCOS patients and control subjects (n ϭ 44). sCD36 and oxLDL were significant independent predictors of glucose and lipid metabolism, whereas hsCRP and IL-6 showed no significant contribution. RESULTSFollowing pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3.21 relative units [0.76 -13.6] vs. 2.33 relative units [0.84 -6.46]) and hsCRP decreased (P Ͻ 0.05). No significant changes were measured in body composition.CONCLUSIONS -sCD36 and oxLDL correlated with measures of insulin sensitivity independent of central fat mass. Pioglitazone treatment reduced sCD36 while improving insulinstimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS. Diabetes Care 31:328-334, 2008P olycystic ovary syndrome (PCOS) is characterized by anovulation, hyperandrogenemia, and/or polycystic ovaries. About 50% of PCOS patients fulfill the criteria of the metabolic syndrome. A five-to eightfold increased risk for type 2 diabetes in PCOS patients compared with weight-matched female control subjects makes the syndrome of high socioeconomic importance (1). Previous studies found significantly increased risk of hypertension and coronary heart disease in women with irregular cycles, suggesting a 4-to 11-fold increased risk for coronary heart disease (2). Increased risk factors for coronary heart disease in PCOS patients were documented in several previous studies, including atherogenic lipid profiles, increased coronary artery calcification, and echocardiographic abnormalities (3).Abdominal obesity is seen in overweight and in most normal-weight PCOS patients. Abdominal obesity, especially visceral adiposity, is associated with insulin resistance and increased levels of inflammatory markers including highsensitive C-reactive protein (hsCRP) and cytokines. Previous studies (4,5) reported higher levels of inflammatory markers in PCOS patients compared with weightmatched control subjects.CD36 is expressed on the surface of monoytes and macrophages (6). CD36 may initiate ...

show abstract

“…Interestingly, TZDs may benefi t cardiovascular parameters, such as lipids, blood pressure, infl ammatory biomarkers, endothelial function and fi brinolytic state Haffner et al 2002). Moreover, they have been successfully used in non-diabetic insulin resistant conditions such as polycystic ovary syndrome (Romualdi et al 2003;Glintborg et al 2005).…”

Section: Introductionmentioning

confidence: 99%

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Chiarelli

Marzio²

2008

VHRM

112

View full text Add to dashboard Cite

Abstract:Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefi t cardiovascular parameters, such as lipids, blood pressure, infl ammatory biomarkers, endothelial function and fi brinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.

show abstract

Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome

Abstract: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.

Cited by 41 publications

References 54 publications

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Contact Info

Product

Resources

About

Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome

Abstract: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.

Cited by 41 publications

References 54 publications

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment

Peroxisome proliferator-activated receptor-&gamma; agonists and diabetes: Current evidence and future perspectives

Contact Info

Product

Resources

About

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives